Solid Biosciences Inc.

NASDAQ:SLDB

Biotechnology

Healthcare
$6.23 +3.63%

+$0.27 today

Market cap
$695.33M
Beta
2.43
P/E (TTM)
-4.3
EPS (TTM)
-$1.75
52W Low $3.79High $8.87

Volume 1.13M

Average 1.39M

Returns on capital

Solid Biosciences Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-96.8%

avg -44.5%

ROIC

-89.1%

avg -67.9%

ROA

-75.0%

avg -55.9%

Analysis

ROA is currently the strongest return metric at -75.0% versus its period average of -55.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Alexander G. Cumbo

President, Chief Executive Officer & DirectorUSD 1.11M55——

David Tyronne Howton Jr.

Chief Operating Officer & SecretaryUSD 791.72K54——

Gabriel Brooks

Chief Medical OfficerUSD 772.73K4997.24K0.12%

Kevin Tan

Chief Financial Officer & TreasurerUSD 607.18K4899.42K0.13%

Ian F. Smith

Executive ChairUSD 75K603.44K<0.01%

Ilan Ganot

Co-founder, Strategic Advisor to the Chief Executive Officer & DirectorUSD 40K52150.00K0.19%

Annie Ganot

Co-Founder & Vice President of Patient Advocacy————

Nicole Anderson

Senior Director of Investor Relations & Corporate Communications————

Paul Herzich

Chief Technology Officer—4872.64K0.09%

Jessie Hanrahan

Chief Regulatory & Preclinical Operations Officer—5074.32K0.10%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 19, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

28

$2.68M

Net Transaction Value

−$2.68M

Net selling

Most Active

Brooks Gabriel

4 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 19, 26

Brooks Gabriel

Direct

Sell$24.6K
Feb 18, 26

Cumbo Alexander

Direct

Sell$96.9K
Feb 18, 26

Hanrahan Jessie

Direct

Sell$24.1K
Feb 18, 26

Tan Kevin

Direct

Sell$31.5K
Feb 18, 26

Brooks Gabriel

Direct

Sell$0
Feb 18, 26

Howton David T

Direct

Sell$43.5K
Feb 18, 26

Herzich Paul

Direct

Sell$21.1K
Feb 18, 26

Ganot Ilan

Indirect

Sell$15.5K
Feb 4, 26

Cumbo Alexander

Direct

Sell$315.1K
Feb 4, 26

Ganot Ilan

Indirect

Sell$46.4K

1–10 of 28

Summary

Insiders reported 0 buys worth $0.00 and 28 sells worth $2.68M over the last 12 months. That adds up to net selling of $2.68M. Brooks Gabriel was the most active insider with 4 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/AN/A
N/A5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Solid Biosciences Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about SLDB's management, answered from reported figures.

Who manages SLDB?

Solid Biosciences Inc. (SLDB) lists 10 active executives. The top listed executive is David Tyronne Howton Jr., Chief Operating Officer & Secretary.

Are SLDB insiders buying or selling?

Recent insider activity shows net buying of $47.78M.